BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22397815)

  • 1. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.
    Lazarevic B; Hammarström C; Yang J; Ramberg H; Diep LM; Karlsen SJ; Kucuk O; Saatcioglu F; Taskèn KA; Svindland A
    Br J Nutr; 2012 Dec; 108(12):2138-47. PubMed ID: 22397815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.
    Lazarevic B; Boezelijn G; Diep LM; Kvernrod K; Ogren O; Ramberg H; Moen A; Wessel N; Berg RE; Egge-Jacobsen W; Hammarstrom C; Svindland A; Kucuk O; Saatcioglu F; Taskèn KA; Karlsen SJ
    Nutr Cancer; 2011; 63(6):889-98. PubMed ID: 21714686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
    Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
    J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
    Avgeris M; Stravodimos K; Scorilas A
    Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.
    Kucuk O; Sarkar FH; Sakr W; Djuric Z; Pollak MN; Khachik F; Li YW; Banerjee M; Grignon D; Bertram JS; Crissman JD; Pontes EJ; Wood DP
    Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):861-8. PubMed ID: 11489752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
    Vis AN; van Rhijn BW; Noordzij MA; Schröder FH; van der Kwast TH
    J Pathol; 2002 Jun; 197(2):148-54. PubMed ID: 12015737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies.
    Ricciardelli C; Bianco-Miotto T; Jindal S; Dodd TJ; Cohen PA; Marshall VR; Sutherland PD; Samaratunga H; Kench JG; Dong Y; Wang H; Clements JA; Risbridger GP; Sutherland RL; Tilley WD; Horsfall DJ;
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1755-65. PubMed ID: 20615888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
    Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
    Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.
    Amamoto R; Yagi M; Song Y; Oda Y; Tsuneyoshi M; Naito S; Yokomizo A; Kuroiwa K; Tokunaga S; Kato S; Hiura H; Samori T; Kang D; Uchiumi T
    Cancer Sci; 2011 Mar; 102(3):639-47. PubMed ID: 21205079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy.
    Beer TM; Myrthue A; Garzotto M; O'hara MF; Chin R; Lowe BA; Montalto MA; Corless CL; Henner WD
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2225-32. PubMed ID: 15598784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells.
    Bühler P; Wolf P; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Freudenberg N; Elsässer-Beile U
    Oncol Rep; 2010 Feb; 23(2):465-70. PubMed ID: 20043108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: identification of novel targets.
    Takahashi Y; Lavigne JA; Hursting SD; Chandramouli GV; Perkins SN; Barrett JC; Wang TT
    Mol Carcinog; 2004 Oct; 41(2):108-119. PubMed ID: 15378649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.